Kiromic BioPharma Announces Closing of Initial Public Offering
October 20 2020 - 4:15PM
Business Wire
Kiromic BioPharma, Inc. (the “Company”), a target discovery and
gene-editing company utilizing artificial intelligence and a
proprietary neural network platform with a therapeutic focus on
immuno-oncology, today announced the closing of its initial public
offering of 1,250,000 shares of its common stock at a public
offering price of $12.00 per share, for gross proceeds of
$15,000,000, before deducting underwriting discounts, commissions
and offering expenses. In addition, the Company has granted the
underwriters a 45-day option to purchase up to an additional
187,500 shares of common stock at the initial public offering
price, less the underwriting discount, to cover
over-allotments.
The shares began trading on the Nasdaq Capital Market on October
16, 2020 under the ticker symbol “KRBP.”
ThinkEquity, a division of Fordham Financial Management, Inc.
acted as sole book-running manager for the offering. Paulson
Investment Company, LLC acted as co-manager for the offering.
A registration statement on Form S-1 (File No. 333-238153)
relating to the shares was filed with the Securities and Exchange
Commission (“SEC”) and became effective on October 15, 2020. The
offering was made only by means of a prospectus. Copies of the
final prospectus may be obtained from ThinkEquity, a division of
Fordham Financial Management, Inc., 17 State Street, 22nd Floor,
New York, New York 10004, by telephone at (877) 436-3673, by email
at prospectus@think-equity.com.
About Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc. is a target discovery and gene-editing
company utilizing artificial intelligence and our proprietary
neural network platform with a therapeutic focus on
immuno-oncology. For more information on Kiromic BioPharma, Inc.,
please visit the company’s website: www.kiromic.com
Forward-Looking Statement Disclaimer
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Kiromic’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully in the section titled “Risk Factors” in the final
prospectus related to the public offering filed with the Securities
and Exchange Commission. Forward-looking statements contained in
this announcement are made as of this date, and Kiromic undertakes
no duty to update such information except as required under
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201020006161/en/
Tony Tontat Chief Financial Officer (844) 539-2873
bus.dev@kiromic.com
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From Apr 2024 to May 2024
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From May 2023 to May 2024